Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
December 5, 2008
The results of this observational study suggested Lipitor was more effective than simvastatin. This is not terribly surprising. Lipitor is the more potent statin, even allowing for dosing differences. Observational studies, however, have inherent weaknesses in that we cannot be sure that the patients were really comparable between the two treatments. Notably an even more potent statin, Crestor (rosuvastatin) was not included in the analysis. Given Pfizer's ferocious marketing engine, this study is likely to be heavily promoted by Pfizer, and its importance exaggerated.
April 9, 2007
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes | www.annals.org
This article confirms what many of us had expected. Enenatide works, as predicted, with a TZD with comparable reductions in A1c to other settings. Many physicians had been previously using the combination "off label" The study allowed the label to be modified to include the combination, and it is now actively being promoted by the durg company.
Page : 11 to 2 of 2
February 7, 2012
What do the cloud, collaboration and virtualization have in common?
January 27, 2012
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Gene therapy success threatens drugs for hemophilia and rare diseases
December 13, 2011
Medtech M&A activity accelerates in 2011
November 30, 2011